Portal de investigación
ESTUDIO OBSERVACIONAL INTERNACIONAL, MULTICÉNTRICO, PROSPECTIVO Y DE COHORTE PARA EVALUAR LA INCIDENCIA DE DIARREA INDUCIDA POR QUIMIOTERAPIA EN PACIENTES CON CÁNCER DE MAMA O COLORRECTAL.
Datos básicos
- Protocolo:
- HEL-QUI-2013-01
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL DE MANISES
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
Cancer worry at higher-risk sample of hereditary cancer in Spain.
Costa-Requena G, Richart-Aznar P, Segura-Huerta Á
Article. 10.1097/CEJ.0000000000000862. 2024
Comparison of psychological distress for breast, ovarian and colorectal cancer predisposition in a Spanish sample at high risk of hereditary cancer.
Costa-Requena, Gema; (...); Segura-Huerta, Angel
Article. 10.1097/CEJ.0000000000000734. 2022
Characterizing diversity in the immune profile by a transcriptomic customized gene signature to potentially personalize treatment in advanced gastric cancer patients
Cabeza-Segura, M; (...); Fleitas, T
Meeting Abstract. 10.1016/j.annonc.2021.08.1541. 2021
Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma
Cabeza-Segura, Manuel; (...); Fleitas, Tania
Article. 10.1038/s41416-022-02005-z. 2022
M2 macrophages could promote an immunosuppressive phenotype in a prospective cohort of advanced gastric cancer patients
Cabeza, M; (...); Fleitas, T
Meeting Abstract. 10.1016/j.annonc.2020.08.1986. 2020
Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families
Fonfria, M; (...); Martinez-Duenas, E
Article. 10.3390/jpm11060548. 2021
Psychiatric symptoms in a Spanish sample with hereditary cancer risk.
Costa-Requena G; (...); Segura-Huerta Á
Article. 10.1007/s12687-022-00580-5. 2022
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)
Aparicio, Jorge; (...); Maurel, Joan
Article. 10.1007/s12094-022-02868-x. 2022
Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)
Aparicio, J; (...); Maurel, J
Meeting Abstract. 10.1016/j.annonc.2021.08.937. 2021
SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019).
Martín-Richard M; (...); Sastre J
Article. 10.1007/s12094-019-02259-9. 2020
SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021).
Fernandez-Montes, Ana; (...); Martin-Richard, Marta
Article. 10.1007/s12094-022-02801-2. 2022
SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023).
Rivera, Fernando; (...); Fleitas Kanonnikoff, Tania
Article. 10.1007/s12094-024-03600-7. 2024
Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation.
Piñana JL; (...); de la Camara, Rafael
Article. 10.1093/infdis/jiad268. 2024